$303 Million is the total value of RTW INVESTMENTS, LP's 29 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 52.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $53,976,000 | +25.9% | 573,361 | +7.4% | 17.83% | +33.8% |
| LJPC | Buy | La Jolla Pharmaceutical Co | $29,279,000 | -2.5% | 1,084,416 | +0.4% | 9.67% | +3.7% |
| OMER | Buy | Omeros Corp | $28,618,000 | +432.9% | 1,819,341 | +271.3% | 9.45% | +466.7% |
| KITE | Buy | Kite Pharma Inc | $25,815,000 | +23.5% | 418,935 | +11.6% | 8.53% | +31.3% |
| DRNA | Buy | Dicerna Pharmaceuticals Inc | $23,890,000 | +45.1% | 2,012,662 | +0.4% | 7.89% | +54.3% |
| ACHN | Sell | Achillion Pharmaceuticals Inc | $21,460,000 | +19.9% | 1,988,914 | -23.2% | 7.09% | +27.5% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $20,748,000 | -18.3% | 2,010,501 | -9.8% | 6.85% | -13.2% |
| MRTX | Sell | Mirati Therapeutics Inc | $12,180,000 | -26.6% | 385,456 | -20.0% | 4.02% | -22.0% |
| ATRA | New | Atara Biotherapeutics Inc. | $11,460,000 | – | 433,923 | +100.0% | 3.78% | – |
| FPRX | Sell | Five Prime Therapeutics Inc | $10,675,000 | -2.8% | 257,236 | -64.0% | 3.53% | +3.3% |
| AGEN | Buy | Agenus Inc | $10,054,000 | +4.9% | 2,214,453 | +6.3% | 3.32% | +11.5% |
| CLDX | Sell | Celldex Therapeutics Inc | $9,992,000 | +31.9% | 637,238 | -11.3% | 3.30% | +40.2% |
| SSRG | Buy | Symmetry Surgical Inc | $8,093,000 | +12.6% | 879,623 | +8.9% | 2.67% | +19.7% |
| BMY | Buy | Bristol-Myers Squibb Co | $7,546,000 | +24.4% | 109,701 | +7.1% | 2.49% | +32.3% |
| CORI | Buy | Corium International Inc | $6,040,000 | +12.3% | 743,865 | +29.3% | 2.00% | +19.4% |
| GBT | Buy | Global Blood Therapeutics Incord | $5,663,000 | +45.4% | 175,156 | +89.6% | 1.87% | +54.4% |
| DYAX | Buy | Dyax Corp | $4,356,000 | +97.8% | 115,795 | +0.4% | 1.44% | +110.4% |
| RGNX | Buy | Regenxbio Inc | $3,674,000 | -18.4% | 221,326 | +8.2% | 1.21% | -13.3% |
| LPCN | Buy | Lipocine Inc | $2,851,000 | +13.4% | 220,515 | +3.8% | 0.94% | +20.6% |
| AXDX | New | Accelerate Diagnostics Inc | $2,309,000 | – | 107,467 | +100.0% | 0.76% | – |
| IVTY | Buy | Invuity Inc | $1,789,000 | -27.1% | 202,808 | +15.9% | 0.59% | -22.4% |
| CYTR | Buy | CytRx Corp | $1,247,000 | +16.0% | 470,576 | +3.8% | 0.41% | +23.4% |
| BPMX | Biopharmx Corp | $563,000 | +47.4% | 370,636 | 0.0% | 0.19% | +56.3% | |
| NVLS | Nivalis Therapeutics Inc | $232,000 | -40.4% | 30,000 | 0.0% | 0.08% | -36.4% | |
| VIVO | VIVO 01/15/2016 CALL 20call | $110,000 | +120.0% | 1,252 | 0.0% | 0.04% | +125.0% | |
| ADAP | Buy | Adaptimmune Therapeutics-adrsponds adr | $85,000 | +1.2% | 7,055 | +0.4% | 0.03% | +7.7% |
| NVRO | New | NVRO 05/20/2016 PUT 50put | $37,000 | – | 142 | +100.0% | 0.01% | – |
| BRKB | New | Berkshire Hathaway Inccl b new | $7,000 | – | 50 | +100.0% | 0.00% | – |
| USO | USO 01/15/2016 CALL 25call | $7,000 | -83.3% | 13,850 | 0.0% | 0.00% | -84.6% | |
| Exit | Berkshire Hathaway Inccl b new | $0 | – | -50 | -100.0% | -0.00% | – | |
| VCYT | Exit | Veracyte Inc | $0 | – | -25,000 | -100.0% | -0.04% | – |
| ELGX | Exit | Endologix Inc | $0 | – | -15,000 | -100.0% | -0.06% | – |
| GHDX | Exit | Genomic Health Inc | $0 | – | -15,000 | -100.0% | -0.10% | – |
| NTRA | Exit | Natera Inc | $0 | – | -31,693 | -100.0% | -0.11% | – |
| BCRX | Exit | BCRX 12/18/2015 CALL 12call | $0 | – | -2,000 | -100.0% | -0.13% | – |
| MDRX | Exit | Allscripts Healthcare Solutions Inc | $0 | – | -48,000 | -100.0% | -0.18% | – |
| MASI | Exit | Masimo Corp | $0 | – | -25,900 | -100.0% | -0.31% | – |
| NLNK | Exit | NewLink Genetics Corp | $0 | – | -28,291 | -100.0% | -0.32% | – |
| OSUR | Exit | OraSure Technologies Inc | $0 | – | -322,996 | -100.0% | -0.45% | – |
| VBIV | Exit | Vbi Vaccines Inc | $0 | – | -650,000 | -100.0% | -0.53% | – |
| RPRX | Exit | Repros Therapeutics Inc | $0 | – | -232,830 | -100.0% | -0.54% | – |
| CBIO | Exit | Catalyst Biosciences Inc | $0 | – | -380,806 | -100.0% | -0.55% | – |
| LENS | Exit | Presbia Plc | $0 | – | -350,000 | -100.0% | -0.60% | – |
| BMY | Exit | BMY 01/15/2016 CALL 60call | $0 | – | -7,500 | -100.0% | -0.80% | – |
| Exit | Atara Biotherapeutics Inc. | $0 | – | -262,995 | -100.0% | -2.57% | – | |
| Exit | Arrowhead Research Corp | $0 | – | -2,097,185 | -100.0% | -3.75% | – | |
| BLUE | Exit | bluebird bio Inc | $0 | – | -151,594 | -100.0% | -4.03% | – |
| INCY | Exit | Incyte Corp | $0 | – | -303,212 | -100.0% | -10.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.